Reuters -- Bristol-Myers Squibb Co’s shares rose more than 5 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.
Reuters -- Bristol-Myers Squibb Co’s shares rose more than 5 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.